J. Goldman & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Goldman & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.12M	Buy	+12,311	New	+$5.46M	0.16%	176
2025 Q3	–	Sell	-1,045	Closed	-$465K	–	625
2025 Q2	$465K	Buy	+1,045	New	+$482K	0.01%	385
2024 Q2	–	Sell	-4,236	Closed	-$1.77M	–	605
2024 Q1	$1.77M	Buy	+4,236	New	+$1.79M	0.06%	230
2023 Q3	–	Sell	-1,750	Closed	-$616K	–	493
2023 Q2	$616K	Buy	+1,750	New	+$590K	0.02%	280
2023 Q1	–	Sell	-30,168	Closed	-$8.71M	–	493
2022 Q4	$8.71M	Buy	+30,168	New	+$9.19M	0.43%	71
2022 Q2	–	Sell	-11,970	Closed	-$3.12M	–	478
2022 Q1	$3.12M	Buy	11,970 +6,708	+127%	+$1.59M	0.14%	169
2021 Q4	$1.16M	Buy	+5,262	New	+$1.02M	0.06%	248
2021 Q2	–	Sell	-29,508	Closed	-$6.34M	–	527
2021 Q1	$6.34M	Buy	+29,508	New	+$6.48M	0.2%	128
2017 Q3	–	Sell	-23,500	Closed	-$3.03M	–	412
2017 Q2	$3.03M	Buy	+23,500	New	+$2.83M	0.16%	144

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

J. Goldman & Co's VRTX Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 12,311 shares worth $6.12M. The stake represents 0.16% of the portfolio and ranks #176 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in VRTX as recently as Q2 2025.

J. Goldman & Co first reported a position in VRTX in Q2 2017 and has held it in 9 quarters since. The position peaked at $8.71M in Q4 2022. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

J. Goldman & Co held 12,311 shares of Vertex Pharmaceuticals worth $6.12M as of Q2 2026.
Vertex Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
Vertex Pharmaceuticals made up 0.16% of J. Goldman & Co's portfolio in Q2 2026, its #176 holding.
J. Goldman & Co first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 9 quarters since.
J. Goldman & Co's Vertex Pharmaceuticals position peaked at $8.71M in Q4 2022.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.